Weiss Stéphanie, Tzavara Eleni T, Davis Richard J, Nomikos George G, Michael McIntosh J, Giros Bruno, Martres Marie-Pascale
Inserm U513, Créteil F-94000, France.
Neuropharmacology. 2007 Jun;52(7):1496-508. doi: 10.1016/j.neuropharm.2007.02.002. Epub 2007 Feb 24.
Mice lacking the dopamine (DA) transporter (DAT) gene exhibit a phenotype reminiscent of schizophrenia and attention deficit hyperactivity disorder (ADHD), including hyperDAergia, hyperactivity and deficits in cognitive performance, which are alleviated by antipsychotic agents. Numerous studies suggest a dysfunction of nicotinic neurotransmission in schizophrenia and show increased tobacco intake in schizophrenic and ADHD patients, possibly as a self-medication. Thus, we examined the potential alteration of nicotinic neurotransmission in DAT knock-out (KO) mice. We showed that constitutively hyperDAergic DAT KO mice exhibited modifications in nicotinic receptor density in an area- and subtype-dependent manner. In some DAergic areas, the small decrease in the beta2* nicotinic subunit (nAChR) density contrasted with the higher decrease and increase in the alpha6* and alpha7 nAChR densities, respectively. Mutant mice were hypersensitive to the stimulant locomotor effects of nicotine at low doses, probably due to enhanced nicotine-induced extracellular DA level. They also showed hypersensitivity to the hypolocomotion induced by nicotine. In contrast, no hypersensitivity was observed for other nicotine-induced behavioral effects, such as anxiety or motor activity in the elevated plus maze. Co-administration of nicotinic agonists at sub-active doses elicited opposite locomotor effects in wild-type and DAT KO mice, as reported previously for methylphenidate. Interestingly, such a co-administration of nicotinic agonists induced synergistic hypolocomotion in DAT KO mice. These findings show that a targeted increase of DA tone can be responsible for significant adaptations of the cholinergic/nicotinic neurotransmission. This study may provide potential leads for the use of nicotine or combined nicotinic agonists for the therapy of psychiatric disorders.
缺乏多巴胺(DA)转运体(DAT)基因的小鼠表现出类似于精神分裂症和注意力缺陷多动障碍(ADHD)的表型,包括多巴胺能亢进、多动和认知能力缺陷,抗精神病药物可缓解这些症状。大量研究表明,精神分裂症中烟碱能神经传递功能失调,且精神分裂症和ADHD患者的烟草摄入量增加,这可能是一种自我治疗方式。因此,我们研究了DAT基因敲除(KO)小鼠中烟碱能神经传递的潜在改变。我们发现,组成型多巴胺能亢进的DAT KO小鼠在烟碱受体密度上呈现区域和亚型依赖性改变。在一些多巴胺能区域,β2烟碱亚基(nAChR)密度略有下降,而α6和α7 nAChR密度分别有更大程度的下降和上升。突变小鼠对低剂量尼古丁的兴奋运动效应过敏,这可能是由于尼古丁诱导的细胞外多巴胺水平升高所致。它们对尼古丁诱导的运动减少也表现出过敏。相比之下,未观察到对其他尼古丁诱导的行为效应过敏,如高架十字迷宫中的焦虑或运动活动。如先前对哌甲酯的报道,在野生型和DAT KO小鼠中,亚活性剂量的烟碱激动剂共同给药会引起相反方向的运动效应。有趣的是,这种烟碱激动剂的共同给药在DAT KO小鼠中诱导了协同性运动减少。这些发现表明,多巴胺水平的靶向升高可能导致胆碱能/烟碱能神经传递的显著适应性变化。本研究可能为使用尼古丁或联合烟碱激动剂治疗精神疾病提供潜在线索。